PDF(Pubmed)
Abstract：
Classical Hodgkin Lymphoma (cHL) is a highly curable disease, but around 20% of patients experience progression or relapse after standard frontline chemotherapy regimens. Salvage regimens followed by autologous stem cell transplants represent the historical treatment approach for these cases. In the last decade, with the increasing understanding of cHL biology and tumor microenvironment role in disease course, novel molecules have been introduced in clinical practice, improving outcomes in the relapsed/refractory setting. The anti-CD30 antibody-drug conjugated brentuximab vedotin and PD-1/PD-L1 checkpoint inhibitors represent nowadays curative options for chemorefractory patients, and randomized trials recently demonstrated their efficacy in frontline immune-chemo-combined modalities. Several drugs able to modulate the patients\' T-lymphocytes and NK cell activity are under development, as well as many anti-CD30 chimeric antigen receptor T-cell products. Multiple tumor aberrant epigenetic mechanisms are being investigated as targets for antineoplastic compounds such as histone deacetylase inhibitors and hypomethylating agents. Moreover, JAK2 inhibition combined with anti-PD1 blockade revealed a potential complementary therapeutic pathway in cHL. In this review, we will summarize recent findings on cHL biology and novel treatment options clinically available, as well as promising future perspectives in the field.
摘要：
经典霍奇金淋巴瘤（cHL）是一种高度可治愈的疾病，但约20%的患者在标准一线化疗方案后出现进展或复发.自体干细胞移植后的挽救方案代表了这些病例的历史治疗方法。在过去的十年里，随着人们对cHL生物学和肿瘤微环境在疾病过程中的作用的日益了解，在临床实践中引入了新的分子，改善复发/难治性患者的结局。抗CD30抗体-药物结合的本妥昔单抗vedotin和PD-1/PD-L1检查点抑制剂代表了当今化学难治性患者的治疗选择，和随机试验最近证明了它们在一线免疫-化疗联合模式中的有效性。几种能够调节患者T淋巴细胞和NK细胞活性的药物正在开发中，以及许多抗CD30嵌合抗原受体T细胞产物。正在研究多种肿瘤异常表观遗传机制作为抗肿瘤化合物的靶标，例如组蛋白脱乙酰酶抑制剂和低甲基化剂。此外，JAK2抑制与抗PD1阻断相结合揭示了cHL中潜在的互补治疗途径。在这次审查中,我们将总结cHL生物学的最新发现和临床上可用的新治疗方案，以及该领域有前途的未来前景。
